Lacombe, Catherine

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment

Cited by 1,776

Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition

Jacque, N., Ronchetti, A. M., Larrue, C., Meunier, G., Birsen, R., Willems, L., Saland, E., Decroocq, J., Maciel, T. T., Lambert, M., et al. (2015) · Blood

Cancer, Hypoxia, and MetabolismAcute Myeloid Leukemia Research

Cited by 387

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

Green, A. S., Chapuis, N., Trovati Maciel, T., Willems, L., Lambert, M., Arnoult, C., Boyer, O., Bardet, V., Park, S., Foretz, M., et al. (2010) · Blood

Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancer

Cited by 199

Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis

Forejtnikovà, H., Vieillevoye, M., Zermati, Y., Lambert, M., Pellegrino, R. M., Guihard, S., Gaudry, M., Camaschella, C., Lacombe, C., Roetto, A., et al. (2010) · Blood

Erythropoietin and Anemia TreatmentIron Metabolism and Disorders

Cited by 152

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells

Poulain, L., Sujobert, P., Zylbersztejn, F., Barreau, S., Stuani, L., Lambert, M., Palama, T. L., Chesnais, V, Birsen, R., Vergez, F., et al. (2017) · Leukemia

Cancer, Hypoxia, and MetabolismPI3K/AKT/mTOR signaling in cancer

Cited by 145